

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

: Jeffrey M. Friedman,

EXAMINER:

G.D. Draper

PATENT 600-1-162

et als.

SERIAL NO.

08/586,594

ART UNIT

1812

FILED

January 16, 1996

FOR

DB, THE RECEPTOR FOR LEPTIN, NUCLEIC ACIDS ENCODING THE RECEPTOR, AND USES THEREOF

CERTIFICATE OF MAILING UNDER 37 CFR 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to the ASSISTANT COMMISSIONER FOR PATENTS, WASHINGTON, DC 20231 on September 2, 1997.

<u>David A. Jackson, Reg. #26,742</u> (Name of Registered Representative) (Signature and Date)

RESPONSE TO RESTRICTION REQUIREMENT UNDER 35 U.S.C. §121

RECEIVED

GPOUP 1800

ASSISTANT COMMISSIONER FOR PATENTS WASHINGTON, D.C. 20231

Dear Sir:

This is in response to a Requirement for Restriction mailed March 31, 1997 requiring Applicant to elect between the following groups of claims for further prosecution:

Group I - Claims 1-14, 63, 66, drawn to various Ob receptor proteins, several point mutations and various compositions, classified in classes 530 and 514 or possibly 424, subclasses 350, 2+ and 401 respectively.

Group II - Claims 15-19, drawn to antigenic fragments and derivative thereto (Polymer conjugates), classified in classes 530, 424 subclasses 326+ and 185.1 respectively.

Group III - Claims 20-28, 34-48, 51-52, drawn to nucleic acids (NA) encoding Ob receptors (ObR), vectors, host cells and methods of making the variant forms of the OBR, classified in classes 435 and 536, subclasses 69.1+ and 23.5 respectively.

Group IV - Claims 29-33, 49-50 drawn to various partial nucleic acid pieces, such as oligo's (various different oligo's), antisense and ribozymes, classified in classes 514 and 536, subclasses 44+ and 24.3+ respectively-depending on the length and use of these products.

Group V - Claims 53-58 drawn to antibodies to ObR and hybridoma, classified in classes 530, subclass 388.22 and 70.21.

Group VI - Claims 59-62, drawn to methods of measuring leptin in various samples using antibodies, classified in class 435, subclass 7.1.

Group VII - Claims 64-65, drawn to methods of treating weight disorders such as obesity using OB-R compositions, classified in classes 514, subclasses 2+.

In accordance with 35 U.S.C. §121, Applicant hereby elects to prosecute the claims of Group I, Claims 1-14, 63, 66, drawn to various Ob receptor proteins, several point mutations and various compositions, classified in Classes 530 and 514 or possibly 424, subclasses 350.2+ and 401, with traversal.

Specifically, the proteins and mutations thereof of Group I are those which would be of interest in the various applications related to the development of assays to interact with the receptor. Likewise, the nucleic acids and fragments thereof would be similarly related, inasmuch as particular interest resides with those nucleic acids or fragments thereof that would code for the expression of the proteins of Group I. Accordingly, the Examiner is asked to reconsider and withdraw at least in part, the present requirement for restriction.

In view of the above, early action on the merits is courteously solicited.

Respectfully submitted,

DAVID A. JACKSON

Attorney for Applicant Registration No. 26,742

KLAUBER & JACKSON 411 Hackensack Avenue Hackensack, NJ 07601 (201) 487-5800